RESULTS	The most commonly reported events were hepatobiliary laboratory abnormality ( 1.7 % ) , general somatic discomfort ( 1.7 % ) , and epigastric pain ( 0.8 % ) in the group that received the generic formulation , and myalgia ( 1.7 % ) , epigastric pain ( 0.9 % ) , and elevation of creatinine phosphokinase ( 0.9 % ) in the group that received the branded formulation .\